主要文件

查看所有文档

CDS022971

拉帕替尼

Name: 拉帕替尼
Brand: ALDRICH

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₉H₂₆ClFN₄O₄S

化学文摘社编号:

231277-92-2

分子量:

581.06

UNSPSC Code:

12352200

PubChem Substance ID:

329796232

MDL number:

MFCD09264194

NACRES:

NA.21

Form:

solid

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

description

Aldrich^CPR

form

solid

SMILES string

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI key

BCFGMOOMADDAQU-UHFFFAOYSA-N

Gene Information

human ... EGFR(1956), ERBB2(2064)

说明

General description

拉帕替尼是一种以表皮生长因子受体ErbB1和ErbB-2为靶点的酪氨酸激酶抑制剂。据报道它与曲妥珠单抗联合使用时在乳腺癌中具有互补作用和抗肿瘤增效活性。

Other Notes

请注意，Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现的研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方承担确认产品标识和纯度的责任。所有销售均为最终销售。

尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。

Still not finding the right product?

Explore all of our products under 拉帕替尼

pictograms

GHS07

signalword

Warning

hcodes

H319,H362,H413

Hazard Classifications

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

pcodes

P202 - P260 - P263 - P273 - P305 + P351 + P338 - P308 + P313

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.

Aleksandra Simiczyjew et al.

Cancers, 10(9) (2018-09-20)

Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth

Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.

Daniel S W Tan et al.

Nature medicine, 23(10), 1167-1175 (2017-09-19)

Targeting EGFR is a validated approach in the treatment of squamous-cell cancers (SCCs), although there are no established biomarkers for predicting response. We have identified a synonymous mutation in EGFR, c.2361G>A (encoding p.Gln787Gln), in two patients with head and neck

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.

Pengfei Ma et al.

Nature communications, 8(1), 823-823 (2017-10-12)

Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. However, it remains unclear whether and how genomic heterogeneity is constrained during tumor evolution. Here, we sequence a unique cohort of multiple synchronous lung cancers (MSLCs) to determine the

查看所有相关文献

全球贸易项目编号

货号	GTIN
CDS022971-25MG	04061828994106